In the Netherlands, in 1.3% of the patients with advanced NSCLC an anaplastic lymphoma kinase (ALK) fusion is detected, which make these patients eligible for targeted therapy with an ALK TKI (5). This evidence concerns the gene ALK and non-small cell lung carcinoma.